What is PierianDx?
Founded in 2014 and headquartered in Missouri, PierianDx is at the forefront of clinical genomics and informatics. The company specializes in developing and deploying industry-leading technologies, including an IVD-ready knowledgebase and reporting solution, designed to integrate seamlessly across the clinical care spectrum. PierianDx's mission is to drive the adoption of genomics in clinical practice, thereby accelerating the fight against both somatic cancer and hereditary diseases. Their comprehensive approach spans genomic sequencing, biomedical informatics, and decision support at the patient's bedside, making them a key player in the healthcare technology sector.
How much funding has PierianDx raised?
PierianDx has raised a total of $63.5M across 3 funding rounds:
Debt
$1M
Debt
$17.5M
Unspecified
$45M
Debt (2020): $1M with participation from PPP
Debt (2021): $17.5M, investors not publicly disclosed
Unspecified (2021): $45M supported by Health Catalyst Capital Management, OrbiMed, Research Triangle Institute, and Inova Health Systems
Key Investors in PierianDx
Health Catalyst Capital Management
Health Catalyst Capital Management is a private equity firm focused on high-growth healthcare information technology and tech-enabled services businesses in the U.S. market, aiming to improve care quality, access, and affordability through technology.
OrbiMed
OrbiMed is a specialized investment firm with deep expertise across the healthcare sector, including biopharmaceuticals, medical devices, digital health, diagnostics, and services, supporting companies at various stages of development.
Research Triangle Institute
Research Triangle Institute is an organization involved in research and development, likely contributing expertise or strategic alignment to PierianDx's advancements in diagnostics and therapeutics.
What's next for PierianDx?
The recent major strategic investment signals a period of accelerated growth and market expansion for PierianDx. This capital infusion is expected to bolster the company's efforts in enhancing its clinical genomics technologies and expanding its reach to healthcare systems, laboratories, and patients globally. PierianDx is poised to further solidify its position as a leader in precision medicine, driving innovation in cancer diagnostics and the application of targeted therapeutics.
See full PierianDx company page
